entertainment -WSS

entertainment

author：explore 2025-10-06 07:54:53 - browse：61442

JOSEPH PREZIOSO/AFP via Getty Images

Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval.

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. The study also found that the drug was generally safe, with fewer patients on the medication reporting adverse events than those who had taken a placebo. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint. And in the bunionectomy study, the opioid comparator beat VX-548 on pain relief.

“While this study was not explicitly designed to test VX-548 vs. the opioid comparator, this may complicate the prescribing decision in the acute setting, where patients often take a short course of treatment and efficacy is a primary consideration,” Stifel market analyst Paul Matteis wrote in a note to investors, adding that results from three Phase 3 studies were positive overall.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： State of the Union pitch: Bigger Medicare drug price negotiations

WSS

A new approach to psychiatric drug development

For AI in health care standards, federal regulators join with industry group

Chamber of Commerce, DOJ clash in court over drug prices

The public health thinking behind the CDC’s new Covid guidance

Transgender sports debate: Physicians say bans are health issue

Ozempic has benefits for kidney disease as well as diabetes

Wikipedia

entertainment

hotspot

Activists slam private health insurers over coverage restrictions

Fetal cell organoids grown from amniotic fluid, study finds

Supreme Court strikes down use of affirmative action

IVF doctors demand details after CooperSurgical lawsuit

The high cost of giving birth even with insurance

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Wildfire smoke exposes gaps in outdoor worker protections

Fed up with FDA, ALS advocates consider a take

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

entertainment

Why the drug industry's warnings on the IRA's impact fall short

PBMs drew scrutiny in House hearing — and so did pharma

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Longer MASH drug regimen improved liver, Akero study finds

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Akili changes sales model for its ADHD video game treatment

Wikipedia

explore

knowledge

Wikipedia